Linka Thomas, Sartory Gudrun, Wiltfang Jens, Müller Bernhard W
Clinic for Psychiatry and Psychotherapy, Rheinische Kliniken Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Neurosci Lett. 2009 Sep 29;463(1):26-30. doi: 10.1016/j.neulet.2009.07.038. Epub 2009 Jul 16.
The intensity dependent amplitude change of auditory evoked potentials (IDAP), an assumed indicator of the level of central nervous serotonergic neurotransmission, was measured in major depressive disorder (MDD, DSM-IV: 296.2, 296.3; APA 1994) before and after treatment with either a selective serotonin reuptake inhibitor or a selective noradrenaline reuptake inhibitor antidepressant and compared with the results of a healthy control group. Auditory evoked P1, N1, P2, P1/N1 and N1/P2 peak-to-peak amplitudes were evaluated in 26 in-patients with MDD prior to and after antidepressant treatment with citalopram (24 days, n=14) or reboxetine (25 days, n=12), and in 43 healthy control subjects. Clinical symptoms of MDD were assessed by means of standardized psychiatric rating scales (CGI, HDRS, HAMA and BDI). The IDAP within the control group remained stable over 24 days (N1 amplitude slope retest ANOVA p=.79). Neither applied antidepressants nor decrease of HDRS total score during treatment had a significant effect on the IDAP in the patients' sample. The conclusion that the IDAP does not reflect the temporary depressive state in MDD is discussed.
听觉诱发电位的强度依赖性振幅变化（IDAP）被认为是中枢神经5-羟色胺能神经传递水平的一个指标。在重度抑郁症（MDD，DSM-IV：296.2，296.3；美国精神病学会，1994）患者中，在用选择性5-羟色胺再摄取抑制剂或选择性去甲肾上腺素再摄取抑制剂抗抑郁药治疗前后，测量了IDAP，并与健康对照组的结果进行比较。对26例MDD住院患者在接受西酞普兰（24天，n = 14）或瑞波西汀（25天，n = 12）抗抑郁治疗前后以及43例健康对照者，评估了听觉诱发的P1、N1、P2、P1/N1和N1/P2峰峰振幅。通过标准化的精神病学评定量表（CGI、HDRS、HAMA和BDI）评估MDD的临床症状。对照组内的IDAP在24天内保持稳定（N1振幅斜率重测方差分析p = 0.79）。所应用的抗抑郁药以及治疗期间HDRS总分的降低，对患者样本中的IDAP均无显著影响。文中讨论了IDAP不能反映MDD患者暂时抑郁状态的结论。
